Skip to content
Company Analysis

Twist Bioscience Corporation TWST

A comprehensive view of key metrics, scores, and financial health for Twist Bioscience Corporation

Overview of Twist Bioscience Corporation

TWST NMS
Healthcare Diagnostics & Research Framework: Medical Devices & Diagnostics Mid Cap
Twist Bioscience Corporation (TWST), is a Mid Cap company, in the Diagnostics & Research industry, last closed at $129.04, about 95.9% overvalued vs fair value, +321.3% 1Y return, ranked 629/1145 in sector.
Metrics Rev Growth 20.3% ROE -16.4% Gross Margin 50.7%
USD 129.04
-15.54%
(Delayed)
• Vol 90d: 99.6%
52-Week Range
Market Cap
$8.09B
Enterprise Value
$7.97B
Overall Score
View breakdown
Overall
Growth
Fair
Profitability
Fair
Health
Weak
Efficiency
Fair
Valuation
Weak
Growth
Fair
Profitability
Fair
Health
Weak
Efficiency
Fair
Valuation
Weak
Completeness: 88%
Confidence: 91%
Updated: Oct 31
Top Beats

Quick Facts

Website https://www.twistbioscience.co...
HQ South San Francisco, CA
Employees 979
Fiscal year Sep 30

Next Events

Earnings Nov 12 Call: Nov 12

Fair Value Snapshot

Bear Base Bull
$4
$5
$7
Current: $129.04 -96% vs base

Engine Room Money Flow™

Mid Cap

Medical Devices & Diagnostics - Where revenue goes and how value is created

Flow Steps
Total Revenue
$376.6M
20.3%%
Gross Profit
$191.0M
43.2%%
Operating Income (GAAP)
-$136.3M
38.3%%
EBITDA
-$111.4M
22.9%%
Money Flow Bridge
Flow Direction: Money moves from left to right
Components: Breakdown shows composition of each stage
Industry-Specific: Medical Devices & Diagnostics

Quality & Reliability Indicators

Gross Margin
50.7%
Good

Gross Profit / Revenue — primary moat signal for MedTech. ≥65% indicates IP-protected consumables with strong pricing power.

Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium

Owner's Pocket - Capital Allocation

Total Returned to Shareholders

Combined dividends, buybacks, and debt reduction

$16.0K

Where It Leaks

Cash Flow Health critical
Significant cash flow inefficiencies identified. Multiple high-impact leaks require attention.
1
Active Leaks
0/1
Improving
0
High Impact
1
Critical
Moat Analysis Medical Devices & Diagnostics

Competitive Advantage Assessment

Evaluating Twist Bioscience Corporation's durable competitive advantages across 6 defense dimensions

Overall Moat Strength
50
/100
Developing
Scores based on quantitative metrics and qualitative factors
Full moat analysis

Key strengths

  • Improving FCF Trend FCF trend score is positive (score 0.85). Improving FCF margin signals compounding operational leverage.
  • Conservative Leverage Leverage position is conservative vs peers (score 0.64). Balance sheet flexibility is a strategic asset for serial acquirers.

Key risks

  • Weak Capital Return Profile Capital return quality is below peers (score 0.36). Low ROIC raises questions about M&A discipline and pipeline ROI.
  • Weak FCF Generation FCF margin quality lags peers (score 0.37). Below-peer FCF conversion is a MedTech quality warning.

The dashed ring is the peer median. Defense scores are percentile ranks against peers, so 50 is roughly the typical company in this group.

Upgrade to unlock the signals and evidence behind each defense.

Premium access

Unlock full defense analysis

Get key signals, strengths, and risks for every moat dimension.

Upgrade to Premium Unlock all moat defenses and evidence.

Pricing Power & Consumable Moat

Developing
48
Premium

Signals, strengths and risks for Pricing Power & Consumable Moat

Premium

Signals, strengths and risks for R&D Pipeline & Capital Returns

Premium

Signals, strengths and risks for FCF Quality & Cash Conversion

Premium

Signals, strengths and risks for Commercial Execution

Premium

Signals, strengths and risks for Capital Structure & Resilience

Premium

Signals, strengths and risks for Growth Durability

Trade-Off Ledger™

Where management spends the performance budget - Growth, Profitability, or Safety

Healthcare: MedTech (Devices & Supplies) vs Industry Peers 75% Coverage
Trade-Off Triangle Visualization A ternary plot showing TWST's balance between Growth (45.0%), Profitability (25.6%), and Safety (29.4%). Growth 45% Safety 29% Profitability 26%

Click axes to expand details. Marker shows current allocation.

3-Year Trend Analysis Locked
Upgrade to unlock the full 3-year trend analysis and deltas.

Growth

75th percentile vs peers
76
Key Signals
Rev Growth YoY 20.3% 79p Revenue CAGR 3Y 22.8% 77p EPS Growth YoY 63.9% 73p Asset Growth YoY 4.5% 59p
Strengths
  • Growth above peer median with strong metric coverage (75%)
Risks

No significant risks identified for this axis.

Profitability

43th percentile vs peers
43
Key Signals
Strengths
Risks
Premium
Unlock full Profitability drilldowns

See the signal-level drivers and insights behind this axis. Upgrade to reveal the full Trade-Off Ledger.

Upgrade Now

Safety

49th percentile vs peers
49
Key Signals
Strengths
Safety drilldowns are available to premium members.

Two Futures

Scenario-based fair value ranges for Twist Bioscience Corporation.

Loading valuation model...
Unable to Compute Fair Value

This company cannot be valued using standard models.

What this means: The Scenario Theatre requires financial data (revenue, cash flow, shares outstanding) to calculate fair value estimates. This data may be unavailable for:

  • Recently listed companies (IPOs, SPACs)
  • Shell companies or holding companies
  • Companies that haven't filed recent financials
  • Foreign companies with limited data coverage
X.X%
X%XX%
X.X%
-XX%XX%
XX.X%
-XX%XX%
Adjust the sliders above to explore different valuation scenarios.
Unlock Premium
Reveal the full Scenario Theatre
See live sliders, narratives, and full Bear/Base/Bull outcomes.
Upgrade Now
Bear
-
- - -
- upside
-
Base
$5.33
- - -
-95.9% vs current
Snapshot base estimate
Bull
-
- - -
- upside
-
Fair Value Range Current: $-
$- $- $-
Actions & Info
Send Feedback
Please select a category.
0/1000